Cell and Gene Therapy Today—May 14, 2026

This week’s Gene and Cell Therapy update highlights regulatory updates, clinical progress, platform advances, partnerships, and manufacturing developments.

In Today’s Newsletter

Dive deeper

🧬 MHRA proposes updated GTMP classification [1] [UK • 11 May 2026]

https://www.europeanpharmaceuticalreview.com/mhra-proposes-modernisation-of-gene-therapy-products-classification/2135424.article
Context: MHRA is seeking feedback on proposed changes to UK gene therapy medicinal product definitions through 22 Jun 2026.
Key point: The proposal would cover recombinant or synthetic nucleic acid moieties and sequence-specific genome editing mechanisms.
Implication: May clarify developer pathways while keeping existing GTMP regulatory principles intact.

🩺 Fractyl cleared for first-in-human RJVA-001 trial [2] [Netherlands • 11 May 2026]

https://ir.fractyl.com/news-releases/news-release-details/fractyl-health-authorized-initiate-first-human-trial-rjva-001
Context: RJVA-001 (Fractyl Health; Rejuva Smart GLP-1 platform) is a beta-cell-targeted AAV gene therapy for type 2 diabetes.
Key point: Fractyl received Netherlands Clinical Trial Application authorization for a Phase 1/2 first-in-human study.
Implication: May influence prescriber choice and payer reviews pending full data.

👁️ Capsida highlights ocular capsids and closes CNS trials [3] [US • 12 May 2026]

https://capsida.com/capsida-to-present-preclinical-data-of-new-next-generation-high-performing-ocular-capsids-at-asgct-annual-meeting/
Context: Capsida will present pre-clinical intravitreal and suprachoroidal ocular AAV capsid data at ASGCT 2026.
Key point: Capsida said its engineered ocular capsids showed broad retinal distribution and expression versus existing serotypes and clinical capsids.
Implication: Signals pipeline investment and modality expansion.

🧪 Merck becomes Genetix testing provider [4] [Germany • 07 May 2026]

https://www.merckgroup.com/en/news/genetix-bioreliance-agreement-07-05-2026.html
Context: Merck signed a five-year agreement with Genetix Biotherapeutics covering analytical and biosafety release testing.
Key point: The deal covers three FDA-approved gene therapies for sickle cell disease, β-thalassemia, and cerebral adrenoleukodystrophy.
Implication: Supports commercial testing infrastructure for advanced therapy release and reliability.

🧫 Rznomics wins FDA RMAT designation for RZ-001 [5] [US • 08 May 2026]

https://www.koreabiomed.com/news/articleView.html?idxno=31583
Context: RZ-001 (Rznomics; ribozyme-based RNA editing platform) is in development for hepatocellular carcinoma.
Key point: Rznomics said FDA granted RMAT designation after early clinical signals from interim Phase 1b/2a data.
Implication: May support closer FDA interaction and faster regulatory planning, pending additional data.

🧠 Cellular Intelligence licenses Novo’s STEM-PD [6] [US • 11 May 2026]

https://www.fiercebiotech.com/biotech/novo-finds-new-home-parkinsons-cell-therapy-ai-biotech-cellular-intelligence
Context: STEM-PD is a clinical-stage Parkinson’s cell therapy using donor stem cells transformed into neurons for brain transplant.
Key point: Cellular Intelligence licensed STEM-PD from Novo Nordisk and plans a Phase 2 study by year-end 2026.
Implication: Signals pipeline investment and modality expansion.

🚹 BEES-HAUS and BHES-HAUS data move to AUA 2026 [7] [Japan • 07 May 2026]

https://www.businesswire.com/news/home/20260506584358/en/Pioneering-feat-in-regenerative-medicine-the-BEES-HAUS-cell-therapy-Paracrine-effect-and-cell-engraftment-together-healing-urethral-stricture.-Its-simplified-version-BHES-HAUS-results-to-be-presented-in-AUA-2026
Context: BEES-HAUS and BHES-HAUS are autologous buccal epithelial cell approaches for male urethral stricture.
Key point: The source said BEES-HAUS findings were published in Frontiers in Urology and BHES-HAUS results will be presented at AUA 2026.
Implication: May inform future clinical translation after validation and local approvals.

🏭 Andelyn launches LVV Curator platform [8] [US • 12 May 2026]

https://www.prnewswire.com/news-releases/andelyn-biosciences-launches-lvv-curator-platform-bringing-proven-viral-vector-platform-pedigree-to-lentiviral-vector-manufacturing-for-cell-therapies-302769440.html
Context: LVV Curator (Andelyn Biosciences) is a standardized lentiviral vector manufacturing platform for cell therapy developers.
Key point: Andelyn said the platform applies Curator methodology used in AAV programs to scalable LVV GMP manufacturing.
Implication: May reduce development friction for early-phase cell therapy programs seeking clinical manufacturing readiness.

Why It Matters

Regulatory definitions are being updated as gene editing, synthetic nucleic acids, and non-traditional platforms outgrow older categories. [1]
First-in-human and RMAT milestones show continued clinical movement for gene therapy in metabolic disease and oncology. [2][5]
Capsid performance, vector manufacturing, and testing partnerships remain central bottlenecks for scaling cell and gene therapies. [3][4][8]
Cell therapy activity is broadening across neurology, urology, and veterinary medicine, with varied evidence maturity. [6][7]

📚 See the full Cell and Gene Therapy archive on our research hub page.

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🧰 See our full range of services. Discover how we can help you.

🎯 Catch up on the Top Cell and Gene Therapy news from the past two weeks, curated by the LucidQuest team.

🎬 Watch on YouTube.

FAQ

What is MHRA changing for GTMP classification?

MHRA proposed a more technology-neutral definition that includes synthetic nucleic acid moieties and sequence-specific genome editing mechanisms. The change is about classification, not changing GTMP regulatory principles. [1]

What is RJVA-001 from Fractyl Health?

RJVA-001 is a one-time, pancreas-targeted AAV gene therapy designed to enable nutrient-responsive GLP-1 expression in type 2 diabetes. The first-in-human study was authorized in the Netherlands. [2]

What happened to Capsida’s CNS programs?

Capsida disclosed closure of the CAP-002 SYNRGY trial after a patient death from cerebral edema in 2025. It also plans to close CAP-003 in PD-GBA, where no patients were dosed. [3]

What does FDA RMAT designation mean for Rznomics’ RZ-001?

Rznomics said RMAT designation may enable closer FDA consultation and eligibility for expedited regulatory pathways. RZ-001 targets hepatocellular carcinoma using a ribozyme-based RNA editing platform. [5]

Who will develop Novo Nordisk’s STEM-PD now?

Cellular Intelligence licensed STEM-PD and will lead development. The program is a donor stem cell-derived neuron therapy for Parkinson’s disease in a first-in-human trial. [6]

What is Andelyn’s LVV Curator platform for?

LVV Curator is designed to standardize lentiviral vector manufacturing for cell therapy programs, with GMP-oriented process controls and a path to scale-up. [8]

Entities / Keywords

MHRA, Medicines and Healthcare products Regulatory Agency, GTMPs, gene therapy medicinal products, Human Medicines Regulations 2012
Fractyl Health, RJVA-001, Rejuva Smart GLP-1, Revita, type 2 diabetes, AAV gene therapy
Capsida Biotherapeutics, ocular capsids, AAV, intravitreal delivery, suprachoroidal delivery, CAP-002, SYNRGY, CAP-003, PD-GBA, RECK, ADAM15
Merck, BioReliance, Genetix Biotherapeutics, analytical testing, biosafety testing
Rznomics, RZ-001, hepatocellular carcinoma, HCC, RMAT, RNA editing, ribozyme
Novo Nordisk, Cellular Intelligence, STEM-PD, Parkinson’s disease, cell therapy
BEES-HAUS, BHES-HAUS, urethral stricture, autologous buccal epithelial cells, AUA 2026
Andelyn Biosciences, LVV Curator, lentiviral vector, LVV, Curator platform, HEK293, GMP manufacturing